Trial Profile

An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jul 2023 Cosmos partner Sun Pharma expects first sales of Winlevi in Canada in Q4 2023.
20 Jun 2023 According to Cosmo Pharmaceuticals media release, Sun Pharmaceutical Industries Limited has received marketing authorization (Notice of Compliance) from Health Canada for Winlevi (clascoterone cream 1%) to target the hormonal component of acne for Canadian patients in 40 years.
21 Mar 2023 Results from CB03-01-25, CB03-01-26, CB03-01-27 assessing Safety , presented at the American Academy of Dermatology annual Meeting 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com